Prior studies have highlighted TET1’s role in driving the proliferation of insulin-dependent endometrial cancer by enhancing G protein-coupled estrogen receptor expression and PI3K/AKT pathway activation (Xie et al., 2017). Here, AKT1 is linked to endometrial cancer.